Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
Recommended Citation
Charters MA, Frisch NB, Wessell NM, Dobson C, Les CM, and Silverton CD. Rivaroxaban versus enoxaparin for venous thromboembolism prophylaxis after hip and knee arthroplasty. J Arthroplasty 2015; 30(7):1277-1280
Document Type
Article
Publication Date
7-1-2015
Publication Title
J arthroplasty
Abstract
The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012. The purpose of our study was to compare rates of VTE and major bleeding between rivaroxaban and our previous protocol of enoxaparin after THA/TKA. A retrospective cohort study was performed including 2406 consecutive patients at our institution between 1/1/11 and 9/30/13. Patients who did not have unilateral primary THA/TKA or who received other anticoagulants were excluded. Of the 1762 patients included, 1113 patients (63.2%) received enoxaparin and 649 patients (36.8%) received rivaroxaban. This study found no demonstrable differences between these two anticoagulants in rates of VTE, infection, reoperation, transfusion, or major bleeding. Therapeutic, Retrospective comparative study, Level III.
Medical Subject Headings
Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Venous Thromboembolism
PubMed ID
25724111
Volume
30
Issue
7
First Page
1277
Last Page
1280
